Panitumumab Pricing “Bookends” Will Be Avastin, Erbitux, Amgen Says
Executive Summary
Amgen's pending oncologic panitumumab will be priced between Genentech's Avastin and Bristol-Myers Squibb/ImClone's Erbitux, Exec VP-Commercial Operations George Morrow said
You may also be interested in...
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products
Amgen Vectibix Assistance Program May Balance Part B Pricing Pressures
Amgen's pricing strategy for its colorectal cancer therapy Vectibix appears to balance the competing pricing pressures created by Medicare Part B's average sales price-based reimbursement methodology